Therapeutic versus Prophylactic Bemiparin in Hospitalized Patients with Nonsevere COVID-19 Pneumonia (BEMICOP Study): An Open-Label, Multicenter, Randomized, Controlled Trial

Overview of attention for article published in Thrombosis and Haemostasis, December 2021

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (73rd percentile)
Above-average Attention Score compared to outputs of the same age and source (54th percentile)

Mentioned by

policy: 1 policy source

twitter: 3 X users

Citations

dimensions_citation: 43 Dimensions

Readers on

mendeley: 81 Mendeley

Summary Policy documents X Dimensions citations

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 6,905 followers.

Anticoagulant therapy as a treatment MODALITY for #COVID19: unanswered questions https://t.co/t3KPN12UPq https://t.co/O3SHXSQniN 🧵

27 May 2022

Reply Repost Favourite

3/ BEMICOP. (N=65) "In patients with COVID-19 hospitalized with non-severe pneumonia but elevated D-dimer, the use of a short course of therapeutic-dose bemiparin did not improve clinical outcomes compared to standard prophylactic doses." 👉https://t.co/se1

20 Oct 2021

Reply Repost Favourite

Therapeutic vs. prophylactic bemiparin in hospitalized patients with non-severe COVID-19 (BEMICOP): an open-label, multicenter, randomized trial https://t.co/OlxWaVXezm

13 Oct 2021

Reply Repost Favourite

Thieme

Article Metrics

Therapeutic versus Prophylactic Bemiparin in Hospitalized Patients with Nonsevere COVID-19 Pneumonia (BEMICOP Study): An Open-Label, Multicenter, Randomized, Controlled Trial

About this Attention Score

Mentioned by

Citations

Readers on